Kazia Therapeutics Files October 2025 6-K Report
Ticker: KZIA · Form: 6-K · Filed: Oct 7, 2025 · CIK: 1075880
| Field | Detail |
|---|---|
| Company | Kazia Therapeutics LTD (KZIA) |
| Form Type | 6-K |
| Filed Date | Oct 7, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $1.39 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, sec-filing
Related Tickers: KZA
TL;DR
Kazia Therapeutics (KZA) filed its October 6-K, confirming 20-F reporting for foreign private issuers.
AI Summary
Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on October 7, 2025. The company, based in Sydney, NSW, Australia, is a foreign private issuer and is submitting its report under the Securities Exchange Act of 1934. This filing is for the month of October 2025 and indicates the company files annual reports under Form 20-F.
Why It Matters
This filing provides an update on Kazia Therapeutics' regulatory reporting status as a foreign private issuer, which can affect how investors interpret their financial disclosures.
Risk Assessment
Risk Level: low — This is a routine regulatory filing for a foreign private issuer and does not contain new financial or operational information.
Key Players & Entities
- Kazia Therapeutics Limited (company) — Registrant
- Novogen Ltd (company) — Former company name
- 000-29962 (other) — SEC File Number
- 20251007 (date) — Filing Date
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of October 2025.
What is Kazia Therapeutics Limited's SEC file number?
Kazia Therapeutics Limited's SEC file number is 000-29962.
Where is Kazia Therapeutics Limited's principal executive office located?
Kazia Therapeutics Limited's principal executive office is located at Three International Towers Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.
Does Kazia Therapeutics Limited file its annual reports under Form 20-F or Form 40-F?
Kazia Therapeutics Limited files its annual reports under cover of Form 20-F.
What was Kazia Therapeutics Limited's former company name?
Kazia Therapeutics Limited's former company name was Novogen Ltd, with a date of name change on December 28, 1998.
Filing Stats: 810 words · 3 min read · ~3 pages · Grade level 18.2 · Accepted 2025-10-07 17:17:39
Key Financial Figures
- $1.39 million — ake a one-time payment of approximately $1.39 million 15 business days after signing, is resp
Filing Documents
- d90511d6k.htm (6-K) — 14KB
- d90511dex991.htm (EX-99.1) — 13KB
- 0001193125-25-233646.txt ( ) — 29KB
Forward-Looking Statements
Forward-Looking Statements This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as "may," "will," "estimate," "future," "forward," "anticipate," or other similar words. Any statement describing Kazia's future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward looking Agreement, the timing for results and data related to Kazia's clinical and preclinical trials, Kazia's strategy and plans with respect to its paxalisib program, the potential benefits of paxalisib as an investigational PI3K/mTOR inhibitor, timing for any regulatory submissions or discussions with regulatory agencies and the potential market opportunity for paxalisib. Such statements are based on Kazia's current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties associated with clinical and preclinical trials and product development, including the risk that interim or early data may not be consistent with final data, risks related to regulatory approvals, risks related to the impact of global economic conditions, and risks related to Kazia's ability to regain and/or maintain compliance with the applicable Nasdaq continued listing requirements and standards. These and other risks and uncertainties are described more fully in Kazia's Annual Report, filed on Form 20-F with the SEC, and in subsequent filings with the United States Securities and Exchange Commission.